The preparation and stability of DL-α-tocopherol labelled with tritium at high specific activity
✍ Scribed by E. A. Evans; R. F. Phillips
- Publisher
- John Wiley and Sons
- Year
- 1969
- Tongue
- French
- Weight
- 389 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
Hydrogen-tritium exchange labelling methods proved to be unsatisfactory for the preparation of tritiated DL-a-tocopherol at high specific activity. The preparation of a-tocopherol specijcally labelled in the 5-methyl hydrogen positions is described : the method permits specific activities in the curies per millimole range to be readily achieved. The synthesis is also suitable jor preparing tocopherol doubly labelled with tritium and carbon-14. The stability of the tritiated vitamin on storage is discussed.
📜 SIMILAR VOLUMES
## Department of Chemistry Labelled Compounds and Metabolite Synthesis Group 31, avenue Paul Vaillant-Couturier 92220 BAGNEUX (FRANCE) SmOuRY The synthesis of betaxolol, a new 8-blocking agent. labelled with tritium in high specific activity ('19 Ci/mmol) is described. The tritium was incorporated
Dz binding properties, i s described. The pyrrolidine moiety of the molecule i s labelled with tritium by hydrogenation, to a specific a c t i v i t y o f up to 58 Ci/mnol and subsequently reacted with an acid chloride. The specificity o f the label i s confirmed by 'H-"R.
## Abstract Tritiated hydrocarbons may be prepared by Kolbe electrolysis of carboxylic acids which have been labelled by catalytic exchange in tritiated water.
We report an improved method for the synthesis of high specific activity insect [10-3 H]juvenile hormones (JH) I, II, and III which affords both enantiomers of each in high optical purity. A synthetic route for JH I was modified to give higher yields and purity. We increased the specific activity of
We describe herein the synthesis of polybromodiphenylacetic acid (&), a fragment common to the tritiation substrates (a) and (JJ) of the sodium channel blocker, PD-85639 (1) and the angiotensin II inhibitor EXP-655 (2) respectively. Preparation of (a) and (11) followed by reductive debromonation wit